Supernus Pharmaceuticals (LTS:0LB2) Cyclically Adjusted Revenue per Share: $10.47 (As of Mar. 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
87 GF Score
Price $47.95
GF Value $38.94
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Cyclically Adjusted Revenue per Share?

Supernus Pharmaceuticals LTS:0LB2 -0.77% 87 Cyclically Adjusted Revenue per Share is $10.47 as of Mar. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 87/100 and a GF Value™ of $38.94 (Modestly Overvalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $3.603. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $10.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Supernus Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 13.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Supernus Pharmaceuticals was 28.20% per year. The lowest was 14.60% per year. And the median was 21.80% per year.

As of today (2026-07-12), Supernus Pharmaceuticals's current stock price is $47.95. Supernus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $10.47. Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Supernus Pharmaceuticals was 7.34. The lowest was 2.92. And the median was 4.81.


Supernus Pharmaceuticals  (LTS:0LB2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.95/10.47
=4.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Supernus Pharmaceuticals was 7.34. The lowest was 2.92. And the median was 4.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Supernus Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Supernus Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.45 6.94 8.42 9.46 10.71

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.57 9.92 10.29 10.71 10.47

LTS:0LB2 vs BCRX, PBH, RGC: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


LTS:0LB2
87GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supernus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.603/330.2130*330.2130
=3.603

Current CPI (Mar. 2026) = 330.2130.

Supernus Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.998 241.018 1.367
201609 1.093 241.428 1.495
201612 1.200 241.432 1.641
201703 1.091 243.801 1.478
201706 1.425 244.955 1.921
201709 1.499 246.819 2.005
201712 1.652 246.524 2.213
201803 1.681 249.554 2.224
201806 1.836 251.989 2.406
201809 1.899 252.439 2.484
201812 2.143 251.233 2.817
201903 1.583 254.202 2.056
201906 1.942 256.143 2.504
201909 1.898 256.759 2.441
201912 1.875 256.974 2.409
202003 1.773 258.115 2.268
202006 2.362 257.797 3.025
202009 2.886 260.280 3.661
202012 2.670 260.474 3.385
202103 2.416 264.877 3.012
202106 2.583 271.696 3.139
202109 2.732 274.310 3.289
202112 2.917 278.802 3.455
202203 2.484 287.504 2.853
202206 2.770 296.311 3.087
202209 3.223 296.808 3.586
202212 2.695 296.797 2.998
202303 2.462 301.836 2.693
202306 2.487 305.109 2.692
202309 2.818 307.789 3.023
202312 2.971 306.746 3.198
202403 2.582 312.332 2.730
202406 3.021 314.175 3.175
202409 3.136 315.301 3.284
202412 3.085 315.605 3.228
202503 2.682 319.799 2.769
202506 2.921 322.561 2.990
202509 3.397 324.800 3.454
202512 3.686 324.054 3.756
202603 3.603 330.213 3.603

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $10.47 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Cyclically Adjusted Revenue per Share of $10.47 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Supernus Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $10.47. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to BCRX and PBH?
Supernus Pharmaceuticals' Cyclically Adjusted Revenue per Share of $10.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $10.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $38.94, compared to a current price of $47.95 — trading 23.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $10.47. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Cyclically Adjusted Revenue per Share is $10.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.95 is trading 23.1% above its estimated GF Value™ of $38.94. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Cyclically Adjusted Revenue per Share: $10.47
  • GF Value™: $38.94 vs. price of $47.95 (23.1% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for LTS:0LB2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.95
Price
$38.94
GF Value